Saturday 17 October 2026
Export TAK’s income statement to Excel — free account
Takeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025. In the quarter to June 2026, revenue grew 1.71%, EPS fell 4.35%, free cash flow fell 95.6% and total debt fell 2.58%, each against the same quarter a year earlier.
19.67
0.22
+1.13%
Follow TAK
| Older periods | Jun '25 | Sep '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
22.92 | — | — | 24.12 |
P/S ratio |
1.62 | — | — | 1.69 | |
P/FCF ratio |
7.65 | — | — | 6.83 | |
P/Operating CF |
32.55 | — | — | 63.00 | |
P/B ratio |
1.02 | — | — | 1.06 | |
Price to Tangible BV |
0.00 | — | — | 0.00 | |
EV/Sales |
2.56 | — | — | 2.62 | |
EV/EBITDA |
9.59 | — | — | 9.41 | |
EV/Operating CF |
7.64 | — | — | 7.05 | |
EV/FCF |
12.11 | — | — | 10.57 | |
Quick Ratio |
0.51 | 0.67 | 0.58 | 0.54 | |
Current Ratio |
1.16 | 1.37 | 1.19 | 1.14 | |
Net Debt/EBITDA |
11.16 | 0.00 | 0.00 | 12.11 | |
Debt/Assets |
32.17% | 32.10% | 31.50% | 31.54% | |
Debt/Equity |
0.66 | 0.65 | 0.63 | 0.65 | |
Asset Turnover |
0.30 | 0.00 | 0.00 | 0.30 | |
Operating CF/Net income |
1.73 | 0.00 | 0.00 | 1.13 | |
Capex/Depreciation |
(0.38) | (0.28) | (0.62) | (0.63) | |
Interest Coverage |
1.72 | — | — | 3.15 | |
Research and Development Expense of Revenue |
13.00% | — | — | 13.72% | |
Selling, General and Administrative Expense of Revenue |
23.12% | — | — | 23.49% | |
Intangible Assets out of Total Assets |
0.62 | 0.60 | 0.60 | 0.59 | |
Share Based Compensation of Revenue |
1.49% | 0.00% | 0.00% | 1.49% | |
Graham Net Nets |
(0.66) | — | — | (0.62) | |
Graham Number |
15.16 | — | — | 15.01 | |
Earnings Yield |
4.36% | — | — | 4.15% | |
Free Cash Flow Yield |
13.07% | — | — | 14.65% | |
Revenue per Share |
2.44 | — | — | 2.43 | |
Operating CF per Share |
0.48 | 0.00 | 0.00 | 0.25 | |
Capex per Share |
(0.15) | 0.00 | 0.00 | (0.20) | |
Free Cash Flow per Share |
0.32 | 0.00 | 0.00 | 0.05 | |
Cash per Share |
0.92 | 0.00 | 0.00 | 1.05 | |
Shareholders Equity per Share |
15.14 | 0.00 | 0.00 | 15.07 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.14 | 0.00 | 0.00 | 15.07 | |
Free Cash Flow |
1,012.51 | 2,198.07 | 4,049.74 | 160.54 | |
Working Capital |
2,370.40 | 5,310.57 | 3,290.66 | 2,430.05 | |
Capital Expenditures |
(473.91) | (352.34) | (2,235.13) | (643.48) | |
Net Current Asset Value |
(31,914.13) | (30,042.33) | (30,213.59) | (31,210.98) | |
EV/EBIT |
26.18 | — | — | 22.54 | |
Capex to Sales |
0.06 | 0.00 | 0.00 | 0.08 | |
Price to Operating Income |
16.54 | — | — | 14.55 | |
| Other line items | |||||
Average Receivables |
4,751.14 | 4,859.18 | 4,878.78 | 5,437.55 | |
Average Payables |
3,342.46 | 2,992.97 | 2,904.35 | 2,925.97 | |
Average Inventory |
8,454.38 | 8,503.82 | 8,614.92 | 8,672.07 | |
Average Assets |
100,441.00 | 101,127.62 | 98,898.05 | 99,191.89 | |
Average Common Equity |
48,783.64 | 49,205.30 | 48,030.65 | 48,293.79 |
Columns are period end dates